Cell & Gene Therapy Manufacturing Services Market Analysis

Mode (Contract manufacturing, In-house manufacturing)

The contract manufacturing segment is poised to hold over 87.8% cell & gene therapy manufacturing services market share by the end of 2037. Companies’ rising outsourcing of manufacturing activities to streamline production procedures and fast-track time-to-market for their therapies is majorly driving the segment’s growth. The dynamic regulatory landscape, in addition to the requirement for flexibility in manufacturing capacity, is driving the growth further. In January 2024, Israeli cell technology company Pluri announced the expansion of the contract development and manufacturing division, PluriCDMO. The company intends to share its knowledge base, technology, and facilities to develop stem cells, induced pluripotent stem cells, exosomes, and Immunotherapeutics, with other businesses.

Type (Cell therapy, Gene therapy)

Based on type, gene therapy is projected to expand at a considerable CAGR during the forecast period in the cell & gene therapy manufacturing services market. A wide range of products are currently up for clinical trials, and manufacturing process improvement has become a significant need in the market. As per an article on gene therapy by Wiley, over 3,900 gene therapy trials were undertaken in 46 countries as per the March 2023 update. Furthermore, prominent companies are increasingly focusing on manufacturing and commercialization owing to rising funding and the clinical success of more products. Companies are undertaking several initiatives to enhance their presence in the manufacturing market.

Our in-depth analysis of the market includes the following segments:

Type	Cell therapy Allogenic Mesenchymal stem cells T-cells Natural killer cells Hematopoietic stem cells Other allogeneic cells Autologous Mesenchymal stem cells T-cells Natural killer cells Hematopoietic stem cells Other allogeneic cells Gene therapy Viral vectors Non-viral vectors
Mode	Contract Manufacturing In-house Manufacturing
Indication	Oncology diseases Cardiovascular diseases Orthopedic diseases Infectious diseases Ophthalmology diseases Other indications
End user	Biopharmaceutical companies Academic research institutes Hospitals

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the cell & gene therapy manufacturing services market was over USD 7.2 billion.

The market size for the cell & gene therapy manufacturing services market is projected to reach USD 58.6 billion by the end of 2037 expanding at a CAGR of 19.1% during the forecast period i.e., between 2025-2037.

The major players in the market are Bluebird Bio, Inc., Catalent, Inc., Charles River Laboratories International, Inc., Merck KGaA, Miltenyi Bioindustry (Miltenyi Biotec), and others.

In terms of mode segment, the contract manufacturing segment is anticipated to garner the largest market share by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to hold the largest market share of 38.9% by the end of 2037 and provide more business opportunities in the future.

Cell & Gene Therapy Manufacturing Services Market Analysis